TheStreet aims to feature only the best products and services. If you buy something via one of our links, we may earn a commission. Why we love this deal The fall months are prime time Read more…
Wall Street is beginning to weigh in on one of the restaurant industry’s newest public stocks, and Bank of America sees considerable room for Jersey Mike’s Subs to expand despite decades of growth. Jersey Mike’s Read more…
TheStreet aims to feature only the best products and services. If you buy something via one of our links, we may earn a commission. Why we love this deal Physical media is making a comeback, Read more…
Allstate’s second-quarter earnings looked strong on the surface, as the insurer reported $3.2 billion in net income, up 56% from 2025, while its overall combined ratio improved to 86.6%. However, Allstate’s (ALL) numbers are less Read more…
At the Federal Reserve Bank of Kansas City’s Jackson Hole Economic Symposium, Fed Chair Kevin Warsh delivered speech, titled In Our Time. The speech touched on many of the key themes Chair Warsh has previously Read more…
EURNZD: ⬆️ Buy – EURNZD reversed from powerful support zone – Likely to rise to resistance level 1.9700 EURNZD currency pair recently reversed from the powerful support zone between the long-term support level 1.9540 (which has been reversing Read more…
EURCHF: ⬇️ Sell – EURCHF reversed from resistance zone – Likely to fall to support level 0.9300 EURCHF currency pair recently reversed from the resistance zone between the pivotal resistance level 0.9400 (which has been reversing the Read more…
If you were hoping airfares would quietly retreat in 2027, United Airlines CEO Scott Kirby just delivered the opposite message. Speaking to reporters Tuesday, Aug. 25, in Newark, Kirby said he expects fares to keep Read more…
A re-escalation of the Canada-U.S. trade war hasn’t prompted a significant downgrade to our economic outlook. We explained why that is here, and answered more pressing questions here. Data releases in the coming week offer Read more…
Alvotech has spent years building a biosimilar platform that Wall Street has struggled to value through regulatory delays, manufacturing investment, and uneven commercial results. Bank of America now thinks the investment case is entering a Read more…